Status:
RECRUITING
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Sudden Deafness
Sudden Sensorineural Hearing Loss
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Migraine and sudden sensorineural hearing loss(SSNHL) are two related disorders. A systemic steroid is usually used to treat SSNHL but the role of migraine prophylaxis medication remained unknown. Meh...
Detailed Description
Once the patients were diagnosed with SSNHL, detailed information of the clinical trial will be introduced. If the patient agreed to participate, he/she will be randomized. The experimental group rece...
Eligibility Criteria
Inclusion
- Age \> 20
- Confirmed diagnosis of unilateral sudden sensorineural hearing loss(SSNHL)
- Treatment started 14 days within onset of SSNHL
Exclusion
- Previous SSNHL history
- Previous middle ear disorder such as chronic otitis media, or previous ear surgery
- Meniere's disease and fluctuating hearing loss patients
- Pregnancy or trying to become pregnant
- Leukemia, hemodialysis, and patients who received chemotherapy before.
- Previous head and neck radiotherapy
- cerebellopontine angle tumors such as vestibular schwannoma
- Patients with moderate to severe hepatic insufficiency
- Patients with major depression disorder or suicide attempt
- Patients with glaucoma
Key Trial Info
Start Date :
October 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT05403229
Start Date
October 17 2022
End Date
September 1 2025
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Taipei Municipal Tucheng Hospital
New Taipei City, Taiwan, 236